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Synopsis: Orofacial granulomatosis (OFG) is an uncommon chronic inflammatory disorder 
of the orofacial region. It is characterised by sub-epithelial non-caseating granulomas and 
has a spectrum of possible clinical manifestations ranging from subtle oral mucosal swelling 
to permanent disfiguring fibrous swelling of the lips and face. Etiopathogenesis is unknown. 
A range of systemic granulomatous disorders including Crohn’s disease and sarcoidosis may 
cause orofacial manifestations that cannot be distinguished from those of OFG. Treatment of 
OFG has proven difficult and unsatisfactory, with no single therapeutic model showing 
consistent efficacy in reducing orofacial swelling and mucosal inflammation.  
 
Key Points:  
 Orofacial granulomatosis (OFG) is an uncommon granulomatous disorder of the orofacial 
tissues. Disease hallmarks include development of disfiguring labial and/or facial 
enlargement and intra-oral mucosal swelling and ulceration. Etiopathogenesis remains 
unknown. 
 Crohn’s disease, sarcoidosis and a range of other systemic disorders can present 
orofacial features similar to those of OFG. However, a strict case definition of OFG 
requires the exclusion of concomitant systemic granulomatous disease.  
 A small subgroup of OFG patients, especially those with disease onset during childhood, 
will eventually develop intestinal Crohn’s disease or, more rarely, sarcoidosis.  
 Management of OFG is challenging and not evidence-based. Prolonged anti-inflammatory 
and immune-modulatory systemic therapy is usually needed to obtain long-term control of 
severe orofacial swelling and inflammation. However intralesional corticosteroid therapy 
may provide notable long-term remission with no need of prolonged treatment.  
 The vast majority of OFG patients on therapy will eventually experience a variable degree 
of reduction in clinical manifestations 
 
Introduction 
Orofacial granulomatosis (OFG) is an uncommon chronic inflammatory disorder that typically 
affects the soft tissues of the orofacial region (1). It is histopathologically characterised by 
sub-epithelial non-caseating granulomas and has a spectrum of possible clinical 
manifestations ranging from subtle oral mucosal swelling to permanent disfiguring fibrous 
swelling of the lips and face (2–6). Painful oral ulceration and neurological manifestations to 
the head and neck region can also occur (3–5). The first cases of a disorder causing 
recurrent/chronic orofacial swelling where initially reported in the nineteenth century 
(Wiesenfeld et al. 1985; James et al. 1986); eventually Melkersson (9) and Rosenthal (10) 
described the association between recurrent/chronic orofacial oedema, facial palsy and 
fissured tongue (lingua plicata). The term Melkersson-Rosenthal syndrome (MRS) was 
therefore introduced to describe individuals with the full triad of manifestations whereas those 
with only labial swelling were referred as having cheilitis granulomatosa (Miescher’s cheilitis). 
In 1985 Wiesenfeld et al introduced the term orofacial granulomatosis (OFG) to encompass 
both MRS and Miescher’s chielits (Wiesenfeld et al. 1985). Over the years a number of 
systemic granulomatous disorders (including Crohn’s disease, sarcoidosis, leprosy, 
tuberculosis, chronic granulomatous disease and possibly deep fungal infections have been 
reported to cause orofacial manifestations (12) similar to those of OFG. It remains 
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controversial whether it is appropriate to refer to them as OFG. The authors of the present 
paper define OFG as an idiopathic granulomatous disease limited to the orofacial tissue, 
namely affecting individuals who do not show any evidence of previous or concomitant 
systemic granulomatous disease as per clinical, radiological, endoscopic, or serological 
investigations; diagnosis of idiopathic OFG remains therefore one of exclusion (3,5,6,13). As 
it is well established that some of these patients would eventually develop additional extra-
oral/facial manifestations of a systemic granulomatous disease (e.g. colonic Crohn’s 
disease), we suggest that their diagnosis should be at that point revised and re-termed (e.g. 
from OFG to oral and colonic Crohn’s disease). This classification has a pragmatic clinical 
relevance, as individuals with OFG limited to orofacial tissues would benefit from therapeutic 
interventions and monitoring that are significantly different from those with a systemic 
granulomatous disease. Orofacial granulomatosis is an uncommon disease. No reliable 
epidemiological data are available as most cases series report small single-centre groups of 
patients (1). There remain few studies describing case series of 100 or more OFG patients, 
which however represent retrospective analysis of cohorts that are often heterogeneous 
(including patients with Crohn’s disease) and observed during two or more decades (1,14). 
Orofacial granulomatosis seems to have no specific ethnic predilection, and most authors 
report that both genders are equally affected (1,15). The disease occurs by the end of the 
third decade of life in the vast majority of reported patients (1).  
 
Orofacial granulomatosis can cause adverse effect upon the quality of life of patients due to 
disfiguring chronic orofacial swelling, painful oral ulceration and occasional neurologic 
involvement (16). Treatment of OFG has proven difficult and unsatisfactory, with no single 
predictable therapeutic model showing consistent efficacy in reducing orofacial swelling and 
mucosal inflammation (17).  
 
The aim of the present paper is to present a comprehensive review of available literature 
about etiopathogenesis, clinical manifestations, prognosis and management of OFG.  
Etiopathogenesis  
Although a number of possible causative factors have been associated to OFG (13), the 
exact etiopathogenesis remains unknown. Existing literature has typically focussed upon the 
role of (i) delayed hypersensitivity to food substances, food preservatives, or dental 
materials, (ii) microbial infections and (iii) inflammatory/immunological factors (13). Recent 
findings regarding the immunopathogenesis of granulomas in Crohn’s disease (18) and other 
rare granulomatous  disorders (19,20) could indicate that similar defects of the innate 
immunity may also play part in the etiology of granulomas of OFG (21–23). Relevant studies 
are ongoing (24). 
 
Hereditary and genetic predisposition: 
There is no adequate data in the literature that supports that OFG has a definite genetic 
background (23,25). Reports of hereditary cases remain scarce and studies have not found 
any convincing robust HLA association (26,27) in OFG patients versus population controls.  
 
Inflammatory/immunological factors: 
Characterisation of granulomatous inflammation of OFG has lead to conflicting and 
inconsistent results. It remains unclear whether lesional T cells of OFG represent clonal 
expansion as a result of chronic antigen stimulation (23,28,29). Studies on the expression of 
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cytokines and chemokines in OFG lesions have found a predominant Th1-mediated immune 
response (23,30).  
Hypersensitivity reactions: 
A wide range of hypersensitivities have been reported in OFG patients including dental 
restorative materials (31,32), toothpastes and other dental hygiene products (33,34), cocoa 
and chocolate (33,34), cinnamon compounds, carvone, carbone piperitone, aspartate  
(33,35–39), carmosine and sun yellow dye (35), monosodium glutamate (35,40), benzoates 
(35,37–39,41,42) and tartrazine (41). Cinnamon and benzoate compounds have been 
suggested to be most common triggers (33–35,38,41,42). A potential role of hypersensitivity 
in OFG pathogenesis seems to be supported and confirmed by patient’s history of symptoms 
aggravation associated with contact or ingestion of one or more of the above triggering 
factors, positive response to elimination diet, and in some cases positive patch testing 
(23,32). Further, a recent paper has reported OFG patients to have a higher prevalence of 
allergy than the general population as demonstrated by their medical history, skin prick test, 
and serum IgE (43). Nevertheless, other studies have failed to find convincing evidence of 
sensitisation to foods, additives or contactants in OFG patients (44). Also outcomes of 
avoidance diet remain controversial as they vary from 14% (14,45) to 70% (46) and seem not 
to correlate with patch testing results (46). It is possible that delayed hypersensitivity 
mechanisms may have a pathogenetic role in a small sub-group of OFG patients.  
 
Microbial factors: 
Several authors have investigated the potential role of microbial agents in triggering the 
immune response of OFG, including M. tuberculosis, M. Paratuberculosis, Saccharomyces 
Cerevisiae, Borrelia burgdorferi, Candida albicans, and Streptococcus mutans. Although 
some studies have reported the presence of M. tuberculosis RNA in OFG samples (47) and 
raised IgG antibody titers to the mycobacterial stress protein 65 (48) in OFG patients’ serum, 
there remains little credible evidence to support a role of any of these agents in the 
aetiopathogenesis of OFG (27,49–52). 
 
Clinical presentation 
Disfiguring lip swelling remains the clinical hallmark of OFG and the most common reason for 
which OFG patients seek medical attention (53). Other possible clinical manifestations 
include swelling and ulceration of the oral mucosa, swelling of facial (other than labial) 
tissues, and neurological manifestations (3,54). It is probable that OFG represent a disease 
with a spectrum of severity that ranges from localized granulomatous inflammation of the 
lips, through orofacial swelling with mucosal ulceration to a disease with additional 
neurological deficit (3,55–57). Available literature indicates that clinical manifestations at 
disease onset can be highly variable and multiform, although permanent disfiguring labial 
and/or facial swelling eventually develops in nearly all affected individuals. 
 
Labial swelling 
Available literature clearly shows that labial enlargement is the most common feature of 
OFG, affecting more than 90% of patients (5). Lip enlargement is typically recurrent and 
oedematous in the early stages of the disease, with each episode lasting few days or weeks. 
(58–60). During the course of the disease and after a number of recurrent episodes the 
swelling of the lips typically becomes persistent, firm and indurated, assuming the 
characteristics of a granulomatous disorder (5). Lip fissuring, exfoliation and impetiginisation 
can be associated, especially in severe cases, and intraoral labial mucosa may become 
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erythematous and granular (5,59). The peri-oral skin may become erythematous and 
exfoliated and some patients may develop angular cheilitis (61). There is no site 
predisposition for the labial swelling although it may be slightly more common on the lower lip 
(3,5,7,62). The swelling rarely causes difficulties in speech or drooling (54). 
Facial swelling: 
Swelling of non-labial facial tissues has been described in OFG patients, sometimes in 
absence of lip enlargement or other clinical manifestations, and can vary in severity. Patients 
can develop recurrent or persistent enlargement of zygomatic, frontal, peri-orbital or 
chin/submental region (3,63), as well as the cheek and eyelids, which represent a diagnostic 
challenge as these are not favourable areas to obtain a biopsy specimen (3). Indeed 
blepharitis granulomatosa (or granulomatous blepharitis) it is likely to represent OFG-like 
disease (64,65). Swelling of submandibular and/or cervical areas due to persistent lymph 
node enlargement can arise in about 25% of OFG individuals (5,54). 
 
Intra-oral manifestations: 
Generalised swelling of the buccal and or labial mucosa gives rise to a cobblestone-like 
appearance (54), a common intra-oral features of OFG (66), particulary in the posterior 
buccal mucosa (54,55). Localised mucosal swelling manifest as discreet painless tags 
typically affect the vestibular buccal and labial mucosa or floor of the mouth (“stag-horning”) 
(5). Deep chronic linear ulcers with raised margins can arise in the buccal and/or labial 
sulcus and are often associated with significant pain (5). Less commonly flat and circular 
aphthous-like ulcers can arise on any oral mucosal surface. Pyostomatitis vegetans, which 
manifests with yellowish, linear pustules on the background of mucosal erythematous “snail 
track ulcerations” has also been described, although the vast majority of reports refer to 
individuals with evidence of inflammatory bowel disease (Crohn’s disease) (4,67–70). 
Painless gingival swelling independent of plaque and calculus deposits may occur in up to 
one third of patients with OFG (2,6,71,72). The swelling can affect the attached and/or free 
gingivae, be localized or generalized, and is often associated with erythema and superficial 
“granular” appearance (2,3). Generalised erythema/inflammation of the oral mucosa is 
uncommonly described as a separate intraoral feature of OFG (73) possibly because it 
usually develops in association with either manifestation including cobblestoning and 
ulceration.  The tongue may have superficial fissures that are most pronounced on the lateral 
aspects of the dorsum (54).  The fissuring may rarely cause food accumulation leading to 
alteration in taste, oral malodour and a local burning sensation (71,74). Fissuring of the 
tongue has been inconsistently associated with neurological manifestations (74). 
 
Neurological manifestations: 
A subgroup of patients with OFG may have lower motor nerve facial palsy at some point in 
the disease course (71,75).  Granuloma formation or inflammation within the course of the 
main stem of the facial nerve is the most probable cause for the palsy (54). The exact 
prevalence of facial palsy in OFG is unclear, but studies report a very wide range of 8-57% 
(3,11,42,76). The palsy can be complete or partial but is typically unilateral. The palsy can 
occur before, with or after (sometimes months to years) the facial swelling (77). It also may 
be accompanied by otalgia and/or changes in hearing and taste (65). Complete recovery of 
nerve function is usual but some residual weakness can occur (75,78,79). Facial palsy can 
be considered as a feature of Melkersson-Rosenthan syndrome when associated with lip 
swelling and fissured tongue, although most clinicians now categorize Melkersson-Rosenthal 
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syndrome as a sub- type of OFG. A number of less common neurological manifestations 
have been reported to develop in up to 30% of OFG patients (2,3,7,76,79). These include 
blepharospasm, migraine-like headache, hypogeusia, glossodynia, hyperacusia, lacrimation 
and sweating (80,81). Relevant pathogenetic mechanisms remain unknown.  
 
Clinical manifestations of early and advanced disease  
Labial swelling is traditionally indicated as the most common clinical feature of OFG and was 
previously reported as being the most frequent manifestation at disease presentation. 
However, a number of authors have more recently suggested that OFG can in fact present 
with multiple, temporary and variable clinical features affecting oral mucosa, gingivae, facial 
tissues and the craniofacial nervous system (3), and that different clinical manifestations can 
develop at different time points during the course of the disease (2,3). Zimmer et al (1992) 
reported that labial swelling was the initial disease manifestation in only 43% of their 42 
patients but this percentage increased to 74% during the course of the disease. Moreover, 
the overall number of clinical manifestations increased during the years as the percentage of 
patients with facial swelling increased from 26% to 50% and those with facial palsy from 19% 
to 33% (2). Mignogna et al (2003) reported that about half of their 19 OFG patients (9/19) 
had an “atypical” disease onset characterized by the absence of labial swelling, which 
however developed in seven of these nine patients at later stage. Al Johani at el studied a 
cohort of 49 OFG patients and confirmed that OFG present with lip swelling in only 50% of 
cases, whereas the remaining individuals had intra-oral or neurological manifestations in 
absence of labial or facial swelling (5). They also reported that the vast majority of patients 
eventually developed a variety of additional features of OFG, with nearly all affected 
individuals (>90%) ultimately developing lip/facial swelling (5). 
 
Systemic association 
Considering the strict definition and nomenclature that the authors of the present review have 
adopted, the concomitant presence of orofacial and other systemic manifestations of a 
specific and well-characterised generalised granulomatous disorder (e.g. Crohn’s disease or 
sarcoidosis) should exclude the diagnosis of idiopathic OFG. Indeed, as mentioned above, a 
diagnosis of “true” idiopathic OFG would require that detailed medical history, clinical 
assessment and comprehensive investigations are performed so to rule out the presence of 
these disorders and confirm that disease is limited to the orofacial tissues (23,25,60). 
Nevertheless, potential associations with systemic disease can still exist in patients with 
idiopathic OFG.  
 
Subsequent development of systemic granulomatous disease  
It is well described that a sub-group of OFG individuals would eventually develop 
manifestations of systemic disease, typically intestinal Crohn’s disease or respiratory/multi-
organ sarcoidosis, even if at the moment of initial assessment there was no clinical, 
serological or radiological evidence of any relevant extra-oral abnormality (59,73,82,83). As 
discussed, it would be sensible at that stage to re-label these cases as, for example, having 
oral and intestinal Crohn’s disease or oral and respiratory sarcoidosis rather than maintaining 
the nomenclature of OFG in association with Crohn’s disease or sarcoidosis. It is difficult to 
predict which OFG patients will eventually develop extra-oral manifestations of a 
granulomatous systemic disease, although the vast majority of them are believed to have 
disease that will remain limited to the orofacial tissues. Campbell et al reported that only 20% 
of OFG patients followed-up in their cohort subsequently developed “true” symptomatic 
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Crohn’s disease (59). They also confirmed previous observations that childhood onset of 
OFG carries at higher risk of subsequent Crohn’s disease development (61,84). There is no 
convincing evidence that any particular clinical manifestation or haematological/histological 
feature in OFG patients might be predictive of future Crohn’s disease development, including 
early asymptomatic intestinal inflammation (see below). 
 
Several cases of multi-systemic sarcoidosis developing in individuals with disease onset 
limited to the orofacial region have been reported (85). Similarly to Crohn’s disease, there 
remains no reliable clinical feature or test to predict development of systemic sarcoidosis in 
individuals with OFG-like disease, with the possible exception of raised serum angiotensin 
converting enzyme (sACE) levels (85). 
 
Concomitant intestinal inflammation of unclear clinical significance 
A variable portion of OFG individuals have been reported to show concomitant endoscopic 
and histological features of intestinal inflammation in absence of specific gastrointestinal 
symptoms and of unclear clinical significance. Both Scully et al in 1982 and Sanderson et al 
in 2005 reported evidence of intestinal inflammation in subgroups of OFG patients with no 
notable history of gastrointestinal symptoms. (34,45,73,86–89). The former study used rigid 
sigmoidoscopy and barium radiology on 19 patients and reported evidence of likely intestinal 
Crohn’s disease in 37% of cases, (82) whereas the latter used flexible endoscopy and 
biopsies, and found discrete granulomatous intestinal inflammation (but no convincing 
evidence of Crohn’s disease) in 54% of the 35 patients studied (73). Clinical significance of 
asymptomatic gut inflammation in these sub-groups of OFG patients is unclear. 
Unfortunately these studies were not followed by a long-term observation and it is unknown 
whether the presence of discrete intestinal inflammation in OFG patients might be predictive 
of subsequent development of symptomatic full-blown Crohn’s disease.  
 
Allergy 
It has been found that an history of IgE-mediated clinical allergy in the form of hay fever, 
eczema, asthma, or oral allergy syndrome can be observed in up to 80% of OFG patients 
compared with 15-20% of the general population (34,43,86–89). The most frequent skin prick 
testing-confirmed sensitizations were to grass, silver birch, ragweed, mugwort, latex and 
pollens (43,45). The clinical significance of IgE-mediated atopy in OFG patients is unclear as 
dietary avoidance of cross-reactive foods failed to demonstrate significant improvements in 
the vast majority of patients (45). Patients with OFG have also been described to have patch 
test-confirmed delayed-type hypersensitivity to a number of food substances and additives 
including wheat, dairy products, chocolates, eggs, peanuts, cinnamaldehyde, carbone 
piperitone, cocoa, carvone, carmosine, sun yellow dye, monosodium glutamate, benzoate, 
and cow’s milk (23). Delayed hypersensitivity to some dental materials including amalgam, 
mercury, gold and cobalt has also been reported (23). Elimination diets and replacement of 
the relevant dental material have been reported to improve clinical manifestations by some, 
albeit not all, authors (23,44). Significant limitations of available studies about dietary 
manipulation include concomitant use of immunosuppressive agents, open label design with 
no controls, and surprising lack of correlation between patch testing result and dietary 
outcome (59,88).  
 
Evaluation and management 
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Diagnosis and assessment 
Diagnosis of OFG requires (i) the presence of relevant oro-facial clinical features, and (ii) the 
exclusion of systemic disorders causing similar manifestations through detailed medical 
history and serological, radiological, and/or endoscopic investigations (where clinically 
justified). Histopathological confirmation of non-caseating granulomas is not a required 
criterion, although it may provide useful information contributing to exclude other causes of 
granulomatous inflammmation (Table 1). There is no consensus with respect the most 
appropriate measure or instrument to assess OFG disease severity/activity and monitor 
response to treatment. Most authors have adopted a pragmatic, although highly subjective, 
patient and/or clinician-centred assessment of swelling and inflammation, and some have 
used standardised clinical photographs to support patients’ and clinicians’ judgement (6). 
Disease severity/activity scores have been suggested by different groups (53,73) but are 
limited by a lack of adequate validation. A newly developed quality of life questionnaire 
known as COMDQ (Chronic Oral Mucosal Diseases Questionnaire) was demonstrated to be 
a valid and reliable measure to assess quality of life in patients with chronic oral mucosal 
diseases including OFG (90). However the number of OFG patients included in COMDQ 
validation study was very small, and further confirmatory evidence is needed. Chiandussi et 
al have proposed an objective method for assessing lip size and treatment-related 
morphological changes based on lip impressions and measurement of related plaster models 
(91).  
 
Management  
The principal goal of OFG therapy is to lessen cosmetically undesirable orofacial swelling 
and control painful mucosal ulceration, however treatment may not be always needed if 
symptoms and/or signs of OFG are mild. A number of treatment strategies have been 
reported during the last 3 decades, but relevant outcomes remain variable and often 
unpredictable. The overall evidence regarding the effectiveness of available therapeutic 
options is not robust due to the lack of randomised control trials and use of inconsistent, 
often subjective, outcome measures. Lack of multicentre collaborations recruiting large 
groups of OFG patients adds further limitations to available data.  
 
Available literature suggests that the treatment of the disfiguring orofacial swelling of OFG 
has proven exceedingly difficult and remains unsatisfactory (17,53). Immunosuppressants, 
tumour necrosis factor alpha inhibitors and other agents, as well as surgical cheiloplasty 
have been used as single or combined therapy with some positive, although overall 
inconsistent, results in a variety of cases reports and small case series (17). Similarly, the 
encouraging results of a benzoate- and cinnamon-free diet reported by White et al. have 
never been replicated by other groups and need further research. Recently a 3-week 
regimen of intralesional triamcinolone acetonide was reported to provide long-term reduction 
of disfiguring orofacial swelling of OFG. 
 
Topical corticosteroid and immunosuppressants 
Topical corticosteroids and tacrolimus applied directly onto the lips and oral mucosa have 
been reported to induce reduction of the labial swelling and oral ulceration in small numbers 
of patients (92,93), although benefits are often temporary and disease can quickly recur 
(5,54). Topical application of corticosteroid and tacrolimus is reported as generally safe with 
a low incidence of adverse side-effects including oral candidosis, mucosal burning sensation, 
sore throat, transient taste disturbance, mucosal staining, and headache (94–99).  
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lntralesional corticosteroids 
lntralesional injections of corticosteroids in the treatment of orofacial swelling of OFG were 
originally introduced in 1971 (100). Initially low concentration triamcinolone acetonide 
(10mg/mL) was used, requiring multiple sessions (12 to 20) of injections at approximately 2 
week intervals in order to obtain a favourable, although transient, clinical response. Local 
block anaesthesia at each session was required becasue of significant pain associated with 
injecting 1-2mL of triamcinolone into affected tissues (101,102). In 1992, Sakuntabhai et al 
suggested using a higher volume of triamcinolone in order to increase efficacy, reduce the 
number of treatment sessions, and attempt long-term swelling remission (103,104). Under 
mental and/or infraorbital nerve blocks with 2% lidocaine, they injected a high volume of 
triamcinolone acetonide (mean 6mL) into the affected lip. Even if swelling increased 
immediately after the injections, their regimen showed to be effective and led to nearly 
complete clinical remission and a long-term swelling-free period (10-12 months). Intralesional 
therapy was further modified in subsequent years with the introduction of highly concentrated 
triamcinolone acetonide (40mg/mL) (105). This formulation allows injection of a high dose of 
triamcinolone within a reduced drug volume, thereby increasing efficacy, reducing associated 
pain and avoiding the need for anaesthetic block (105,106). 
 
The largest cohort of OFG patients managed with triamcinolone injections was reported by 
Fedele et al (107). They described the long-term outcomes of a homogeneous group of 22 
OFG patients who had been managed with a standardised therapeutic regimen of 
triamcinolone injections (107). The treatment led to a significant reduction in orofacial 
swelling, with the majority of patients showing no disease recurrence after a single course of 
therapy for up to 4 years. Those who experienced swelling recurrence responded well to a 
second course of therapy.  Of note, the vast majority of patients reached swelling-free status 
at 2-week time point after the first course of therapy; all patients did so at 1-month time point.  
Adverse side effects of intralesional therapy are uncommon and include local hematoma 
(100,104), skin atrophy, mild transient swelling of the lip (103) hypo/hyper-pigmentation (105) 
and rarely candidiasis (56). 
 
Systemic corticosteroids and immunosuppressants 
Short courses of moderate dosage prednisolone (25-50 mg/day; 0.3-0.7 mg/kg/day) or 
deflazacort (108) (30-60 mg/day;1.2:1 therapeutic dosage ratio to prednisolone) can quickly 
reduce orofacial swelling of OFG (55–57), but benefits are typically short-lived and followed 
by disease recurrences. Long-term corticosteroid therapy is characterised by several 
adverse side effects and therefore systemic immunosuppressants are likely to represent a 
safer options in the long-term management of OFG. A recent report demonstrated a 
significant improvement in lip swelling and erythema after one month of mycophenolate moftil 
(MMF) 500mg twice daily, with sustained benefits and no notable toxicity after 1 year of 
therapy (109). Although azathioprine is commonly used by many clinicians to achieve long-
term immunosuppression and swelling reduction in OFG patients, there remain no papers 
reporting in detail the use of relevant therapeutic regimens and their outcomes (110,111).  
 
Anti-tumour necrosis factor (TNF) agents 
Thalidomide, infliximab and adalimumab have been occasionally used in the therapy of OFG 
in small groups of patients with variable outcomes. Low-dose thalidomide  (20-100 mg daily) 
has been reported to induce notable reduction in OFG-related facial swelling (92,112–115) 
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even after previous failure of other topical and systemic immunosuppressant therapy (92). 
The main limitating factor of thalidomide therapy is represented by its toxicity: in addition to 
its teratogenicity, thalidomide can cause sensory and motor neuropathies, and skin rash 
(92,113,116,117). Infliximab and adalimumab have been used in small groups of patient with 
OFG and with oral manifestations of intestinal Crohn’s disease (118,119). Available evidence 
suggests that infliximab can provide good-short term response in the majority of OFG 
patients (up to 70%), however recurrences are common with only one third of patients being 
still responsive after 2 years (118,119). It has been suggested that patients failing infliximab 
therapy may benefit from adalimumab (118,119). Because of the association with potentially 
serious adverse effects, which include infusion reactions, infection and increased risk of 
malignancy (118) use of infliximab and adalimumab in OFG should mirror that for intestinal 
CD, that is, severe disease and intolerant or resistant to standard systemic therapy.  
 
Diet modification 
A number of studies have attempted treatment of OFG via elimination of potential allergens 
from the diet of affected patients. In addition to multiple case reports of patch test-proven 
hypersensitivity to a single antigen and relevant dietary avoidance (23), an UK group have 
developed three separate dietary interventions aimed at reducing orofacial swelling and other 
intra-oral manifestations of OFG: a cinnamon- and benzoate-free diet (88), a dietary 
avoidance of cross reacting foods in OFG individuals with positive skin prick test to silver 
birch, grass, mugwort, ragweed and latex (45), and a low phenolic acid diet (120). Although 
the authors claim that some of these interventions can reduce orofacial inflammation of OFG 
in up to 70% of cases, there remains little robust evidence regarding their actual 
effectiveness due to methodological limitations of available studies.    
 
Anti-leprotic agents 
Dapsone and clofazimine that have been occasionally reported to reduce the orofacial 
swelling of OFG (55,121–124). In one study, long-treatment with low-dosage clofazimine 
(400-700mg weekly for 3–11 months) led to complete remission in 5 of 10 treated patients 
and partial improvement in a further 3 patients (125). There are only few published cases of 
dapsone therapy in OFG, with relevant results ranging from complete relief to ineffectiveness 
(63). It seems that anti-leprotic agents may be more effective during the early stages of the 
disease (121). 
 
Miscellaneous drugs 
There have been reports of small number of patients with OFG having clinical benefits with 
methotrexate (126), sulphasalazine (127), lymecycline (128), minocycline (129), or 5-amino-
salicylic acid (130), metronidazole (115,131–133) hydroxychloroquine (122), and various 
combinations of these agents with systemic, topical or intralesional corticosteroids.  
 
Surgery and low-level laser therapy 
OFG patients with long-standing and disfiguring fibrotic swelling that has proven to be 
unresponsive to treatment may benefit from surgical correction. Relevant plastic surgery 
procedures include cheiloplasty, commissuroplasty, facial liposuction and tangential 
resection of labial mucosa, submucosa, and muscles (134). It has been recommended that 
surgical correction of OFG should be undertaken during inactive phases of the disease 
(25,122), and possibly in association with perioperative oral or intralesional corticosteroid 
therapy (135–137). The long-term benefits of surgery are largely unknown although 
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recurrence of the labial swelling following surgery has been reported (138,139).  
Merigo et al reported complete remission of labial swelling with the use of low-level laser 
therapy (LLLT) in one OFG patient who had previusly failed to respond to topical and 
systemic corticosteroid and immunosuppressive therapy (140). Low-level laser therapy is 
believed to have anti-inflammatory and wound-healing properties (140). Of note, clinical 
remission was maintained for two years after treatment (140). 
 
Psychological support 
When orofacial enlargement of OFG becomes persistent and aesthetically unacceptable, 
typically in cases of absent or partial response to therapy, psychological support and 
counselling may be beneficial in developing coping mechanisms and improving quality of life 
(127). However there are no studies investigating potential benefits of psychological 
interventions in OFG individuals. 
 
Clinical outcomes 
Although variable and multiform in its early stages, the natural history of OFG is ultimately 
progressive, and permanent disfiguring labial and/or facial swelling eventually develops in 
nearly all affected individuals (53). Spontaneous resolution is exceptionally rare and the vast 
majority of patients would eventually require medical treatment. The long-term prognosis of 
OFG individuals is largely unknown. Al-Jahani et al studied the long-term clinical outcomes of 
49 patients with OFG who received a wide variety of treatments and reported that facial 
swelling of OFG tends to improve over time in those who are on therapy, with approximately 
78% of patients showing some reduction in their clinical manifestations. However, only 
46.8% eventually experienced complete resolution of orofacial swelling (6). Historically a 
variety of different topical and/or systemic agents have been used during the long-term 
management of OFG patients with a variable incidence of development of new 
manifestations, lack of response, and adverse side effects (6). However, more recent and 
better designed studies seem to suggest that some single treatment modalities could 
effectively provide long-term control of the disease, as in the case of intralesional 
corticosteroid injections (53). A summary of clinical outcomes of available interventions is 
provided in (Table 2). 
 
Conclusion 
Orofacial granulomatosis is an uncommon inflammatory disorder that typically affects 
children and young adults and causes disfiguring facial swelling and painful oral ulceration. 
Although a strict case definition of OFG requires the absence of any systemic granulomatous 
disease, an unpredictable subgroup of individuals with OFG limited to the orofacial tissues 
would eventually develop intestinal Crohn’s disease or, more rarely, sarcoidosis. A significant 
number of OFG patients show evidence of concomitant IgE-mediated allergy and delayed-
type hypersensitivity to a number of food and other antigens, although relevant role in 
etiopathogenesis and therapy remains unclear. Management of OFG is often difficult and not 
evidence-based. Mild cases would benefit from topical immunosuppression whereas long-
term anti-inflammatory and immunosuppressive agents are needed to control more severe 
facial swelling and painful oral ulceration. Intralesional corticosteroid therapy may provide 
notable long-term remission with no need of prolonged treatment. It seems that the vast 
majority of OFG patients on therapy would eventually experience a variable degree of 
reduction in orofacial swelling.   
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Tables: 
Table 1. Diagnostic investigations and criteria of orofacial granulomatosis 
Investigations  Results 
Full blood cell count   Should be normal 
Hemoglobin   Should be normal 
Serum angiotensin converting enzyme levels*   Should be normal 
C-1 esterase inhibitor levelsy   Should be normal 
Serum iron and transferrin   Should be normal 
Tuberculin skin test (when clinically justified)   Should be negative 
Chest radiography (when clinically justified)   Should be normal 
GI endoscopy/histopathologyz  Should be normal; if 
inflammatory changes are 
present, Crohn disease 
should be excluded 
Histopathology I: dilated lymphatics, edema of corium, slight 
fibrosis, with/without multiple noncaseating granulomas with 
Langerhans giant cell and lymphocytes 
 
 
 
Should be present§ 
Histopathology II: PAS reaction and Ziehl-Neelsen stain (when 
clinically justified) 
 
 
Should be negative 
Polarized light microscopy: identification of birefringent foreign- 
body material (when clinically justified) 
 
 
Should be negative 
 
GI: Gastrointestinal; PAS: periodic acide-Schiff. 
*To be performed when there are clinical features compatible with potential diagnosis of 
sarcoidosis. 
yTo be performed when orofacial swelling is recurrent and edematous without signs of 
persistent tissue fibrosis. 
zTo be performed when clinical or laboratory features increase suggestion of GI 
inflammatory disease. 
§Absence of histopathological features does not exclude orofacial granulomatosis diagnosis 
if clinical features are compatible. 
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Table 2. Clinical outcomes of OFG therapy 
 
yparehT Clinical outcome Level of 
evidence 
Topical agents: 
 
Corticosteroids (3, 141, 142) 
 
 
Tacrolimus (93) 
 
 
 
Effective in managing moderate intra-oral lesions 
and mild labial swelling.  
 
Marked improvement in lip swelling. Benefits can 
be transient. 
 - 
 
 
D 
lntralesional 
corticosteroids 
 
Low volume triamcinolone 
acetonide [10 mg/mL] (103, 
142, 143)   
 
 
High volume triamcinolone 
acetonide [40mg/ml] (53, 
106) 
  
 
Long term-effective in reducing lip swelling. It 
requires multiple injection sessions and local 
block aneasthesia. Adverse effects: acute pain 
and transient worsening of swelling  
 
Effective in long-term reduction of oro-facial 
swelling. Requires one single 3-weekly course 
and no block anaesthesia. Adverse effects: mild 
discomfort, skin pigmentations.  
D 
Systemic corticosteroids 
and 
immunosuppressants 
 
Prednisolone (57, 141) 
 
 
Mycophenolate mofetil 
(109) 
 
 
 
 
Short-term courses effective in reducing facial 
swelling and oral ulcers. Side effects from chronic 
therapy: osteoporosis, diabetes, cataract, 
Cushing’s syndrome. 
 
Long-term effectiveness in reducing orofacial 
swelling and ulceration. It requires monitoring of 
toxicity. 
D 
Anti-TNF strategies  
 
Thalidomide (92,117,144) 
 
 
Infliximab (117,145–
148,119) 
 
 
 
Adalimumab (149) 
 
 
 
 
 
Effective in the short-term management of OFG. 
Side effect:  Neuropathy and teratogenesis. 
 
Short-term reduction in orofacial swelling and oral 
ulceration. It requires multiple infusions. Adverse 
effects: possible infusion reaction, infection, 
increased risk of cancer. 
 
Satisfactory results for oral ulceration. Adverse 
effects: possible infusion reaction, infection, 
 
 
 
 
 
 
D 
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increased risk of cancer. 
 
Diet modification 
 
Cinnamon- and Benzoate 
free (88) 
 
 
Avoid cross reacting food in 
patients with positive skin 
prick testing (45) 
 
Low phenolic acid diet 
(120) 
 
 
Improvement in swelling and infalmmation. 
Compliance can be a limitation. Patch tests not 
predicitive of response.  
 
Failed to show significant improvement. 
 
 
 
Improvement in swelling and infalmmation. The 
diet was nutritionally inadequate. 
 
 
 
 
 
D 
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